Expression of NOTCH3 exon 16 differentiates Diffuse Large B-cell Lymphoma into molecular subtypes and is associated with prognosis

Ditte Starberg Jespersen(Aalborg University Hospital), Karen Dybkær(Aalborg University Hospital), Teis Esben Søndergaard(Aalborg University), Anna A. Schönherz(Aalborg University Hospital), Hanne Due(Aalborg University Hospital), Martin Bøgsted(Chr. Hansen (Denmark))

Scientific Reports

January 23, 2019

10.1038/s41598-018-36680-x

Cited by 7

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

|Blood|2009|390

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Leukemia|2012|362

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2013|247